Skip to main content

Aarti Drugs Ltd

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. More about the company

₹396.4
-0.03% today
₹3,617 Cr · Small cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is AARTIDRUGS early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
—
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 28
1w13w26w
Week 28 — mature, watch for distribution
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
—
—
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.37x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
MA20 rolling over · -1.9% vs MA50 +0.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.6%
3M
-6.1%
6M
+7.6%
YTD
—
1Y
—
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2026-04-02 → 2026-10-16
S? 28w
2026-04-022026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 28w current
Total tracked: 28 weeks across 1 stage run.
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-16S—
Wk 28 · Vol 0.37x
2026-10-15S—
Wk 28 · Vol 0.41x
2026-10-14S—
Wk 28 · Vol 0.52x
2026-10-13S—
Wk 27 · Vol 0.37x
2026-10-12S—
Wk 27 · Vol 0.34x
2026-10-09S—
Wk 27 · Vol 0.39x
2026-10-08S—
Wk 27 · Vol 1.23x
2026-10-07S—
Wk 27 · Vol 0.74x
2026-10-06S—
Wk 26 · Vol 0.67x
2026-10-05S—
Wk 26 · Vol 0.63x
2026-10-01S—
Wk 26 · Vol 0.86x
2026-09-30S—
Wk 26 · Vol 0.73x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹421.3
200 DMA
—
52W High
—
52W Low
—
5D Low
₹396.4
Resistance levels (recent highs)
20d High
₹437.3
60d High
₹439.4
120d High
₹439.4
250d High
—
Next resistance
+10.3%
to 20d High
P/E (TTM)
18.3
Forward 14.8
Earnings Growth (YoY)
-12.0%
Revenue +6.4%
ROE
+13.4%
Profit margin +7.6%
Dividend Yield
0.51%
P/B 2.3
About this companyHealth Care· Pharmaceuticals

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.